Market Overview

OncoMed Pharmaceuticals Q4 Earnings Preview

Related OMED
41 Stocks Moving In Thursday's Mid-Day Session
46 Biggest Movers From Yesterday
OncoMed Announces Interim Phase –b Results for Navicixizumab and Paclitaxel Combination ... (GuruFocus)

OncoMed Pharmaceuticals (NASDAQ: OMED) unveils its next round of earnings Thursday. Get prepared with Benzinga's ultimate preview for OncoMed Pharmaceuticals's Q4 earnings.

Earnings and Revenue

OncoMed Pharmaceuticals EPS loss is expected to be around 34 cents, according to sell-side analysts. Sales will likely be near $5.2 million.

OncoMed Pharmaceuticals' loss in the same period a year ago was 64 cents per share. Quarterly sales came in at $6.21 million. If the company were to match the consensus estimate when it reports Thursday, sales would be down 16.06 percent from the year-ago period.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:


Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.41   -0.63 -0.68
EPS Actual -0.28 -0.4 -0.61 -0.64


Stock Performance

Over the past 52-week period, shares of OncoMed Pharmaceuticals have declined 67.71 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement

Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The average rating by analysts on OncoMed Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

OncoMed's Q4 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.

Posted-In: Earnings News Previews Trading Ideas


Related Articles (OMED)

View Comments and Join the Discussion!

This Day In Market History: John Galbraith Congressional Testimony Angers Investors

Earnings Preview For MyoKardia